Receptor Pharma is a pharmaceutical company. Its new, proprietary drug candidate RP301 is developed to halt the progression of Alzheimer Disease through the inhibition of a recently discovered signaling pathway. With this approach Receptor Pharma differentiates itself from the AD treatment that recently received (provisional) FDA approval as this drug only treats the effects of the disease, while RP301 inhibits the mechanism causing AD.

Receptor Pharma has secured patent protection around molecules based on a compound recently identified as a ligand for a GPCR that is very strongly correlated to the progression of the pathology of Alzheimer diseases. 

Receptor Pharma is taking an approach that utilizes this newly identified pathway and mechanism circumventing/ avoiding the side effects seen in other, failing AD drug candidates. The R&D started in 0ct 2017 we are 4 y ers ahead of the curve and have been able to secure the scientific support from kOL in the fields of the pathology of Alzheimers  

Study Period: 2018-2026.

To help accelerate discovery, the Coalition Against Major Diseases (CAMD), an alliance of pharmaceutical companies, nonprofit foundations and government advisers, has forged a first-of-its-kind partnership to share data from Alzheimer’s clinical trials. Receptor Pharma is committed to the CAMD initiative and to share our non-clinical and clinical findings in the public domain in a timely manner.

Fast-tracked timeline with less risk than traditional discovery routes, which is key to attract.

Receptor Pharma own’s IP that protects RP301 

Receptor Pharma is a pharmaceutical start up with blockbuster potential

The drug candidate, RP-301 is known to be safe in humans at high dose levels acts at the target receptor protein that is responsible for the overproduction of the destructive beta-amyloid plaques and tau-tangles in the brain (non-clinical in vitro proof of concept in place)

Multiple-Exit points already within 18 / 30 months:

Exit points: 

• Completion of clinical POC of RP30X Q1 2025 
• Start of Ph II of RP301 Q3 2026 
• Sale of commercialization licenses for RP301 Q1 2028 sales

Biotechnology is a science-driven industry sector that uses living organisms and molecular biology to produce healthcare-related products. Biotechnology companies also develop therapeutics. Biotechnology is best known for its role in medicine and pharmaceuticals, but the science is also applied in other areas such as genomics, food production.

KEY TAKEAWAYS

• Biotechnology is the branch of applied science that uses living organisms and their derivatives to produce products and processes.

• These products and processes feature in healthcare, medicine, biofuels, and environmental safety.

• Biotech stocks are risky investments since biotech firms often spend massive amounts of time and money developing drugs that might never get to the market.

• The top U.S.-based biotechnology firms in terms of market capitalization are Johnson & Johnson ($457.2 billion), Roche ($346.3 billion), Pfizer ($262.2 billion), and Novartis ($205 billion)—as of September 1, 2021.

• A valuation of a biotech firm should consider the size and development stage of the asset pipeline.

BREAKING AWAY

Breaking away from big pharma, modern biotechnology continues to make significant contributions to extending the human lifespan and improving quality of life, including providing products and therapies to combat diseases. Novel approaches are using plant based therapeutics or our own metabolites to beat the autoimmune disease, biotech also includes generating higher crop yields, and using bio mass to reduce greenhouse gas emissions.